Exhibit 99.1 News Release Contact: Linsey Wisniewski Corporate Communications 667-218-7700 Emily Duncan Investor Relations 833-447-2783 CONSTELLATION REPORTS THIRD QUARTER 2025 RESULTS Earnings Release Highlights Baltimore (Nov 7, 2025) — Constellation Energy Corporation (Nasdaq: CEG) today reported its financial results for the third quarter of 2025. "We achieved one of the highest operating quarters for our nuclear fleet and advanced major milestones like our historic settlement with Maryland for continue ...

Market Overview - The global market for peripheral vascular devices exceeds $5 billion, with the company's product market estimated at approximately $1 billion[75]. - In Q3 2025, biologics accounted for 54% of worldwide sales, indicating a strong focus on this product segment[78]. - The company expects to hold 22 CE and UKCA approvals by the end of 2025, covering nearly all product offerings in the EU and UK[85]. Sales Performance - Net sales increased by $6.2 million, or 11%, to $61.0 million for the three months ended September 30, 2025, compared to $54.8 million for the same period in 2024[99]. - For the nine months ended September 30, 2025, net sales increased by $21.0 million, or 13%, to $185.1 million, compared to $164.1 million for the same period in 2024[103]. - Direct-to-hospital net sales accounted for 95% of total net sales for both the three and nine months ended September 30, 2025, and 2024[102][104]. - Net sales in the Americas increased by $3.4 million, or 10%, for the three months ended September 30, 2025, compared to the same period in 2024[104]. - EMEA net sales increased by $2.6 million, or 18%, for the three months ended September 30, 2025, compared to the same period in 2024[106]. - APAC net sales increased by $0.7 million, or 6%, for the nine months ended September 30, 2025, compared to the same period in 2024[109]. Financial Metrics - Gross profit for the three months ended September 30, 2025, increased by $8.8 million, or 24%, to $46.0 million, with a gross margin of 75.3%, up from 67.8% in 2024[111]. - For the nine months ended September 30, 2025, the company reported an operating income of $49.1 million, an increase from $39.4 million for the same period in 2024[134]. - Cash and cash equivalents as of September 30, 2025, were $25.5 million, slightly down from $25.6 million as of December 31, 2024[127]. - Net cash provided by operating activities was $58.1 million for the nine months ended September 30, 2025, compared to $28.9 million for the same period in 2024[136][137]. - Net cash used in investing activities was $48.1 million for the nine months ended September 30, 2025, primarily due to purchases of marketable securities totaling $43.0 million[140]. Expenses - Sales and marketing expenses increased by 20% to $41.0 million for the nine months ended September 30, 2025, driven by higher sales representative headcount and wage increases[114]. - General and administrative expenses increased by 18% to $31.6 million for the nine months ended September 30, 2025, primarily due to higher headcount and wage increases[116]. - Research and development expenses decreased by 12% to $10.6 million for the nine months ended September 30, 2025, driven by lower third-party service fees[119]. Strategic Decisions - The company aims to grow its direct sales force and increase average selling prices of devices as part of its business strategy[80]. - The decision to wind down certain product lines resulted in approximately $2.2 million in revenues in 2021 and $0.7 million in 2022[86]. - The transition to direct sales in various countries, including Korea and Thailand, involved termination fees totaling approximately $1.2 million[91]. Regulatory and Taxation - The company received regulatory approvals for multiple products, including the XenoSure patch in Japan and the Artegraft bovine graft in the EU, enhancing market access[84][85]. - The effective income tax rate for the three months ended September 30, 2025, was 23.0%, compared to 23.4% for the same period in 2024[120][121]. - The company recorded a tax provision of $5.2 million on pre-tax income of $22.6 million for Q3 2025, up from a $3.4 million provision on pre-tax income of $14.6 million in Q3 2024[120]. Capital and Dividends - The company authorized a stock repurchase program of up to $75.0 million, which may be executed until February 17, 2026[128]. - The company issued $172.5 million in convertible senior notes due 2030, with a net proceeds of approximately $167.7 million after debt issuance costs[129][130]. - The Board of Directors approved a quarterly cash dividend of $0.20 per share for Fiscal Year 2025, totaling $4,517,000 for the payment on March 27, 2025[144]. - For Fiscal Year 2024, the quarterly cash dividend was $0.16 per share, with total payments of $3,589,000, $3,593,000, $3,596,000, and $3,600,000 for each quarter[144]. Accounting Policies - The company has not made any material changes to its critical accounting policies and estimates as disclosed in the 2024 Form 10-K[146]. - There are no significant changes in foreign currency risk or interest rate risk from the previous disclosures in the 2024 Form 10-K[148].

Acquisition and Expansion - On September 16, 2024, the company completed the acquisition of Alimera Sciences, adding the ILUVIEN® and YUTIQ® products to its portfolio, which are approved for treating diabetic macular edema and non-infectious uveitis, respectively[210]. - The acquisition of Alimera is expected to strengthen the Rare Disease business and expand the company's footprint in Europe, Asia, and the Middle East[214]. - The company incurred approximately $13.2 million in transaction and integration costs related to the Alimera acquisition during the nine months ended September 30, 2024[226]. - The company plans to continue expanding its Rare Disease business through organic growth and acquisitions, focusing on niche opportunities[215]. - The company repaid $72.5 million of Alimera's debt as part of the merger[223]. - Each contingent value right (CVR) from the Alimera acquisition entitles holders to milestone payments based on net revenues exceeding $140 million in 2026 and $160 million in 2027[224]. - The company extended its partnership with Alliance Medical Products, Inc. to support the transition to ILUVIEN and expanded manufacturing capacity through the addition of a second manufacturing line[216]. Financial Performance - Net revenues for Q3 2025 were $227.8 million, a 53.6% increase from $148.3 million in Q3 2024, driven by growth in Rare Disease and Brands[238]. - Rare Disease total net revenues reached $118.5 million in Q3 2025, up 109.9% from $56.4 million in Q3 2024, primarily due to increased sales of Cortrophin Gel and a full quarter of sales from ILUVIEN[236]. - Operating income for Q3 2025 was $36.2 million, compared to a loss of $20.5 million in Q3 2024, marking a substantial turnaround[234]. - Net income for Q3 2025 was $26.6 million, compared to a loss of $24.2 million in Q3 2024, indicating a significant improvement in profitability[234]. - For the three months ended September 30, 2025, total net revenue was $636.3 million, an increase of 50.1% compared to $423.8 million for the same period in 2024[253]. - Rare Disease total net revenues reached $291.4 million, up 104.4% from $142.6 million in the same period last year, driven by increased volume of Cortrophin Gel and sales from ILUVIEN and YUTIQ[253]. Expenses and Costs - Cost of sales for Q3 2025 increased to $93.4 million, a 48.1% rise from $63.1 million in Q3 2024, attributed to significant growth in sales volumes[240]. - Research and development expenses increased by 21.5% to $12.3 million in Q3 2025 from $10.1 million in Q3 2024[244]. - Selling, general, and administrative expenses decreased by 3.1% to $76.7 million in Q3 2025 from $79.1 million in Q3 2024[244]. - The cost of sales as a percentage of net revenues decreased to 41.0% in Q3 2025 from 42.5% in Q3 2024, primarily due to the non-recurrence of inventory step-up costs[241]. - Cost of sales increased to $241.0 million, a rise of 41.8% from $169.9 million in the prior year, attributed to significant growth in sales volumes[257]. - Total other operating expenses increased to $318.9 million for the nine months ended September 30, 2025, up from $248.9 million in 2024, representing a 28.1% increase[259]. - Research and development expenses rose to $39.4 million, a 41.1% increase from $27.9 million in 2024, driven by ongoing and new projects in Rare Disease and Generics[259]. - Selling, general, and administrative expenses increased by 30.6% to $235.0 million from $179.9 million, primarily due to higher employment costs and investments in Rare Disease sales and marketing[259]. - Depreciation and amortization expenses were $68.8 million, up 52.5% from $45.1 million, mainly due to amortization of acquired intangible assets ILUVIEN and YUTIQ[259]. Cash Flow and Financing - Net cash provided by operating activities was $154.9 million for the nine months ended September 30, 2025, an increase of $106.7 million compared to $48.2 million in the same period of 2024[284]. - Net cash used in investing activities for the nine months ended September 30, 2025 was $32.9 million, significantly lower than $394.0 million in the same period of 2024, primarily due to the acquisition of Alimera[285]. - Net cash used in financing activities for the nine months ended September 30, 2025 was $5.3 million, compared to $269.9 million provided in the same period of 2024[286]. - The company entered into a new credit agreement providing for a senior secured term loan facility of $325.0 million and a revolving credit facility of $75.0 million[265]. - The company drew the full $325.0 million of Term Loan A on September 16, 2024, to finance the acquisition of Alimera[266]. - The company issued $275.0 million of Convertible Senior Notes due 2029, with net proceeds of approximately $306.8 million used to repay existing senior secured credit agreements[270]. - The cash interest rate under the Term Loan A was approximately 6.76% as of September 30, 2025[266]. - The Company believes its financial resources will be sufficient to meet working capital requirements and debt obligations for at least the next 12 months[282]. Tax and Other Financial Metrics - The effective tax rate for the three months ended September 30, 2025, was 21.3%, with an income tax expense of approximately $7.2 million[250]. - An income tax expense of approximately $13.5 million was recorded for the nine months ended September 30, 2025, with an effective tax rate of 20.9%[263]. - The company recognized a gain of $14.5 million for contingent consideration fair value adjustments during the three months ended September 30, 2025[247]. - Interest expense, net increased by $2.4 million, primarily due to higher interest expenses related to the New Credit Agreement and Convertible Senior Notes[252]. - The company recorded an unrealized gain on investment in equity securities of approximately $3.1 million for the three months ended September 30, 2025[252]. - Cost of sales as a percentage of net revenues decreased to 37.9% from 40.1% year-over-year, reflecting a shift in product mix[258]. - The Company paid an upfront payment of $75.0 million to EyePoint for a product rights agreement, with additional quarterly payments totaling $7.5 million during 2024[280]. - The Company expects to pay royalties to EyePoint at 30% of annual U.S. net sales of certain products starting at $70.0 million in 2025, increasing annually thereafter[281]. - The Company used approximately $40.6 million of the net proceeds from the offering of the Notes to pay premiums on the Capped Calls[277]. - The Capped Calls cover approximately 4.3 million shares of the Company's common stock, aimed at reducing potential dilution upon conversion of the Notes[278].

Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance PRINCETON, N.J., November 7, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2025. "ANI had another strong quarter in which we delivered record revenue and adjusted EBITDA, underscoring the strength of our Rare Disease and Generics business ...

F e b ru a ry 7 , 2 0 2 3 KKR Reports Third Quarter 2025 Financial Results New York, November 7, 2025 – KKR & Co. Inc. (NYSE: KKR) today reported its third quarter 2025 results. KKR KKR & Co. Inc. Reports Third Quarter 2025 Financial Results K K R & C o. I n c. R e p o r t s T h i r d Q u a r t e r 2 0 2 5 F i n a n c i a l R e s u l t s N o v e m b e r 7 , 2 0 2 5 Conference Call A conference call to discuss KKR's financial results will be held on November 7, 2025 at 9:00 a.m. ET. The conference call may b ...

Financial Performance - Atmus reported net sales of $448 million for Q3 2025, a 10.9% increase from $404 million in Q3 2024[5] - GAAP net income for Q3 2025 was $55 million, or $0.66 diluted earnings per share, compared to $44 million, or $0.52 diluted earnings per share in Q3 2024[9] - Adjusted EBITDA for Q3 2025 was $92 million, with an adjusted EBITDA margin of 20.4%, up from $79 million and 19.6% in Q3 2024[8] - The gross margin increased to $129 million, representing 28.9% of net sales, compared to $111 million and 27.6% in the same period last year[7] - Net income for the nine months ended September 30, 2025, was $159.4 million, compared to $145.5 million for the same period in 2024, reflecting an increase of 9.9%[27] - Basic earnings per share rose to $0.67 for the three months ended September 30, 2025, compared to $0.53 in 2024, marking a growth of 26.4%[29] - Adjusted EBITDA for the three months ended September 30, 2025, was $91.5 million, up from $79.1 million in 2024, indicating a 15.3% increase[31] - The net income margin improved to 12.2% for the three months ended September 30, 2025, compared to 10.8% in 2024[31] Cash Flow and Assets - Cash provided by operating activities was $82 million in Q3 2025, compared to $71 million in Q3 2024[10] - Adjusted free cash flow was $72 million in Q3 2025, an increase from $65 million in Q3 2024[11] - Free cash flow for the three months ended September 30, 2025, was $68.9 million, compared to $54.3 million in 2024, representing a growth of 26.8%[36] - Cash and cash equivalents at the end of the period increased to $218.3 million from $196.8 million, a rise of 10.7%[27] - Total assets increased to $1,339.1 million as of September 30, 2025, up from $1,190.3 million at December 31, 2024, representing a growth of 12.5%[25] Debt and Shareholder Returns - Long-term debt decreased to $547.5 million as of September 30, 2025, from $570.0 million at December 31, 2024, a reduction of 4.4%[25] - The company repurchased $59.8 million of common stock during the nine months ended September 30, 2025, compared to $10.0 million in 2024[27] - A quarterly cash dividend of $0.055 per share was declared, marking a 10% increase from the previous quarter[3] Operational Changes - Atmus completed its operational separation from Cummins Inc., gaining full operational control over its distribution network[4] - The company raised its revenue guidance for 2025 to a range of $1,720 million to $1,745 million[6] Taxation - The effective tax rate for Q3 2025 was 23.6%[10]

Financial Performance - The company reported a significant increase in revenue for the second quarter of fiscal 2026, with a year-over-year growth of 25% compared to the second quarter of fiscal 2025[162]. - The company anticipates a further 30% increase in revenue for the upcoming fiscal year, driven by new product launches and market expansion efforts[162]. - For the three months ended September 30, 2025, net revenue was CAD 66.7 million, a 6% increase from CAD 63.0 million in the same period of 2024[209]. - Net revenue for the six months ended September 30, 2025, increased by 7% to $138.8 million from $129.2 million in the same period of 2024[240]. - Cannabis segment net revenue was $107.8 million for the six months ended September 30, 2025, up from $91.5 million in 2024, reflecting an increase of 18%[242]. - Canadian adult-use cannabis revenue increased to $51.0 million in the six months ended September 30, 2025, a 37% increase from $37.3 million in 2024[243]. - Canadian medical cannabis revenue rose to $43.0 million, a 15% increase from $37.5 million in the prior year, driven by more insured customers and larger order sizes[244]. - International cannabis revenue decreased to $13.8 million, down 17% from $16.8 million in 2024, primarily due to supply chain challenges in Europe[245]. Cost and Margin Analysis - The gross margin percentage decreased to 33% for the three months ended September 30, 2025, down from 35% in the same period of 2024, reflecting a 200 basis points decline[217]. - Gross margin for the Cannabis segment was CAD 15.9 million, or 31% of net revenue, for the three months ended September 30, 2025, compared to CAD 16.2 million, or 36% of net revenue, in the same period of 2024[219]. - Gross margin percentage declined by 600 basis points from 35% in 2024 to 29% in 2025[240]. - The cost of goods sold for the three months ended September 30, 2025, was CAD 44.8 million, a 9% increase from CAD 41.2 million in the same period of 2024[217]. Operating Expenses - Total operating expenses decreased by 43% from $67.8 million in Q2 2025 to $38.8 million in Q2 2026[221]. - General and administrative expenses fell by 14% from $16.8 million in Q2 2025 to $14.4 million in Q2 2026, primarily due to headcount reductions and lower third-party costs[223]. - Sales and marketing expenses increased slightly by 1% from $15.0 million in Q2 2025 to $15.1 million in Q2 2026, driven by higher customer acquisition costs[224]. - Acquisition, divestiture, and other costs decreased by 56% from $3.9 million in Q2 2025 to $1.7 million in Q2 2026[225]. - Loss on asset impairment and restructuring dropped significantly by 98% from $20.8 million in Q2 2025 to $0.5 million in Q2 2026[228]. Profitability and Loss - Net loss from continuing operations significantly improved to CAD 1.6 million for the three months ended September 30, 2025, compared to a loss of CAD 131.6 million in the same period of 2024, representing a 99% reduction in losses[209]. - Net loss from continuing operations decreased by 99% from $131.6 million in Q2 2025 to $1.6 million in Q2 2026, attributed to a significant change in other income[236]. - The net loss from continuing operations decreased to $43.2 million for the six months ended September 30, 2025, compared to a net loss of $260.7 million for the same period in 2024, representing a year-over-year improvement of 83%[265]. - Adjusted EBITDA improved by 45% from a loss of $5.5 million in Q2 2025 to a loss of $3.0 million in Q2 2026, mainly due to cost savings in selling, general, and administrative expenses[238]. - Adjusted EBITDA for the six months ended September 30, 2025, was a loss of $10.965 million, slightly worse than the loss of $10.787 million in the same period of 2024, indicating a 2% increase in loss[268]. Cash Flow and Liquidity - The company has reported a cash flow increase of 20% in the last quarter, improving liquidity and financial stability[162]. - Cash and cash equivalents as of September 30, 2025, were $298.1 million, indicating sufficient liquidity to meet short-term obligations[270]. - Cash used in operating activities decreased to $28.3 million for the six months ended September 30, 2025, compared to $105.6 million for the same period in 2024[278]. - Cash provided by investing activities was $16.0 million for the six months ended September 30, 2025, compared to cash used of $32.0 million in 2024[279]. - Free cash flow for the six months ended September 30, 2025 was an outflow of $30.8 million, significantly improved from an outflow of $112.1 million in 2024[291]. Debt and Financing - The company completed a debt and equity financing transaction resulting in approximately $96.4 million in new senior unsecured convertible debentures and 3,350,430 common share purchase warrants[272]. - Total debt outstanding decreased to $228.2 million as of September 30, 2025, down from $304.1 million as of March 31, 2025[292]. - Long-term debt repayments totaled $71.7 million for the six months ended September 30, 2025, primarily related to the Credit Facility and settlement of debentures[288]. - Interest expense decreased by $23.9 million, from $42.4 million in the six months ended September 30, 2024, to $18.5 million in the same period of 2025, primarily due to reduced debt balances[267]. Market Expansion and Strategic Initiatives - The total user base for the company's cannabis products has expanded by 15% over the past six months, reaching approximately 1.2 million active users[162]. - The launch of new innovative cannabis products, including edibles and beverages, is expected to contribute to a projected gross margin improvement of 5%[172]. - The anticipated legalization of cannabis in additional U.S. states is expected to create new market opportunities, potentially increasing customer base by 40%[165]. - Canopy USA, LLC is being established to accelerate entry into the U.S. cannabis market, with expectations of capturing a significant share of the growing sector[163]. - The company is actively pursuing the acquisition of Jetty, with the final tranche closing expected in Q3 2026, which is anticipated to enhance market presence in the U.S.[163]. Regulatory Compliance - The company is focused on maintaining compliance with evolving regulations, which is critical for sustaining growth and operational efficiency[166]. Segment Reporting - As of June 30, 2025, the company has restructured its reportable segments to two: cannabis operations and Storz & Bickel, focusing on segment net revenue and gross margin for performance evaluation[173]. - Canopy USA holds 100% of Wana and Acreage, and approximately 77% of Jetty, reflecting significant ownership in key cannabis brands[183]. - As of September 30, 2025, Canopy Growth has a non-controlling interest in Canopy USA, having deconsolidated its financial results as of April 30, 2024[181].

EXHIBIT 99.1 Brookfield Asset Management Announces Record Third Quarter Results Fundraised a Record $30 Billion in the Third Quarter Record Fee-Related Earnings Up 19% Over the Last Twelve Months Announced Agreement to Acquire Remaining Interest in Oaktree NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) ("BAM"), a leading global alternative asset manager headquartered in New York with over $1 trillion of assets under management, today announced financial re ...

Exhibit 99.1 News Release Graham Corporation ¨ 20 Florence Avenue t Batavia, NY 14020 IMMEDIATE RELEASE Graham Corporation Reports Second Quarter Fiscal 2026 Results Second Quarter Fiscal 2026 Highlights: BATAVIA, NY, November 7, 2025 – Graham Corporation (NYSE: GHM) ("GHM" or the "Company"), a global leader in the design and manufacture of mission critical fluid, power, heat transfer and vacuum technologies for the Defense, Energy & Process, and Space industries, today reported financial results for its se ...

Exhibit 99.1 TABLE OF CONTENTS | Condensed interim statements of financial position | 1 | | --- | --- | | Condensed interim statements of loss and comprehensive loss | 2 | | Condensed interim statements of cash flows | 3 | | Condensed interim statements of changes in equity | 4 | | Notes to the condensed interim financial statements | 5 | New Found Gold Corp. Condensed Interim Statements of Financial Position (Unaudited - Expressed in Canadian Dollars) | | | September 30, | December 31, | | --- | --- | --- ...